However, recently, a randomised phase II study showed that sequential administration of EGFR-TKI, following chemotherapy, led to a significant improvement in PFS versus administration of chemotherapy alone in unselected, previously untreated patients with advanced NSCLC (Mok et al, 2009b). This evidence concerns the gene EGFR and non-small cell lung carcinoma.